FDA Drug recall D-0855-2022
MVASI (bevacizumab-awwb), Injection, For Intravenous Infusion After Dilution, 100 mg/4 ml, Single dose vial, Rx only, Manufactured by Amgen…
- FDA Drug
- Class II
- terminated
- Published 2022-05-18
On 2022-05-18 the FDA classified a Class II recall of MVASI (bevacizumab-awwb), Injection, For Intravenous Infusion After Dilution, 100 mg/4 ml, Single dose vial, Rx only, Manufactured by Amgen… by Amgen, citing defective container: loose crimp defect, potential loss of container integrity.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-0855-2022 |
| Classification | Class II |
| Status | terminated |
| Initiated | 2022-05-02 |
| Published | 2022-05-18 |
| Last updated | 2026-09-13 11:52 UTC |
| Company | Amgen |
| Distribution | US |
Product
MVASI (bevacizumab-awwb), Injection, For Intravenous Infusion After Dilution, 100 mg/4 ml, Single dose vial, Rx only, Manufactured by Amgen Inc. Thousand Oaks, CA 91320-1799, NDC 55513-0206-01
Reason
Defective container: loose crimp defect, potential loss of container integrity.
Identifiers
| code_info | Lots: 1142258, 1143196, Exp. 09/24 |
|---|
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0855-2022%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.